Tumor News and Research

RSS

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Study reveals tumor and immune cell interactions in craniopharyngiomas

Craniopharyngiomas are brain tumors that negatively impact the hormonal function of the nearby pituitary.

16 Dec 2024

Global study reveals shifting trends in ovarian cancer incidence by subtype and region

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by histological subtypes and regions. It revealed significant geographic disparities, with higher rates in regions with very high HDIs and emphasized the need for targeted prevention and surveillance strategies.

15 Dec 2024

Research sheds light on how hypoxia affects T cell function in cancer

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective.

14 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Study unveils key mechanism behind prostate cancer's uncontrolled growth

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Exploring the cytotoxic potential of neocryptolepine derivatives against cancer

Announcing a new publication for Acta Materia Medica journal. Cancer has been a severe public health and social problem, a leading disease that has diminished the quality of life, and a barrier to improving life expectancy.

13 Dec 2024

Removing a splinter? Treating a wart? If a doctor does it, it can be billed as surgery

When George Lai of Portland, Oregon, took his toddler son to a pediatrician last summer for a checkup, the doctor noticed a little splinter in the child's palm.

13 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

New protein platform enhances cancer immunotherapy

Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either directly modifying immune cells or by creating proteins that help immune cells locate cancer cells. The findings were published today by the journal Nature Biotechnology.

13 Dec 2024

AI revolutionizes cancer research with advanced tools

Significant advancements in understanding the molecular and cellular mechanisms of tumor progression have been made, yet challenges remain.

13 Dec 2024

Disrupting the circadian rhythm of glioblastoma slows tumor growth, study says

Virtually every cell in the human body has an internal clock. These clocks take their cues from a central clock in the brain. In a normal, biological process called synchrony, the central clock coordinates daily rhythms around the body, so that every cell and tissue recognizes the same external time of day.

13 Dec 2024

Lipid imbalances hold the key to chronic inflammation in colon cancer

Scientists uncover how disrupted lipid metabolism fuels chronic inflammation in colorectal cancer, offering insights into new therapeutic strategies targeting pro-inflammatory and pro-resolving lipid imbalances.

12 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024